Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment.
T. Pressiani
No relevant relationships to disclose
L. Rimassa
No relevant relationships to disclose
C. Boni
No relevant relationships to disclose
R. Labianca
No relevant relationships to disclose
S. Fagiuoli
No relevant relationships to disclose
A. Ardizzoni
No relevant relationships to disclose
P. Foa
No relevant relationships to disclose
E. Cortesi
No relevant relationships to disclose
C. Porta
No relevant relationships to disclose
F. Artioli
No relevant relationships to disclose
L. Latini
No relevant relationships to disclose
C. Carnaghi
No relevant relationships to disclose
R. F. Lutman
No relevant relationships to disclose
G. Torzilli
No relevant relationships to disclose
M. Tommasini
No relevant relationships to disclose
R. Ceriani
No relevant relationships to disclose
G. Covini
No relevant relationships to disclose
L. Giordano
No relevant relationships to disclose
N. Locopo
No relevant relationships to disclose
A. Santoro
No relevant relationships to disclose